The future of drug development will rely on artificial intelligence, because biology is too complex for humans to understand
RNA as a therapeutic modality has arrived on a global scale with new medicines approved for rare disease and as vaccines. This is only the beginning. Everyone will face a genetic condition in their lifetime. And, because RNA therapies can be programmed to precisely target genetic causes, we can conceive of addressing most genetic conditions. Finding therapies requires mining RNA biology data. But, this data is vast, complex and overwhelming, making standard approaches to drug discovery too slow and costly.
Deep Genomics has the solution: Our AI Platform untangles the complexity in RNA biology, identifies novel targets, and evaluates thousands of possibilities to identify the best therapeutic candidates.
We seek to program therapies for any gene and any genetic condition.
Our proprietary AI Platform is designed for data-driven prediction, positive feedback loops, and exponential growth.
In 2018, our proprietary AI Platform unlocked our first targets in which RNA splicing was the defect and the mechanism for correction. In 2023 we released the first Foundation Model for RNA Biology, BigRNA.
We are currently developing BigRNA+, which will expand the number of mechanisms and genetic variants we can pursue. This includes expanding into more complex genetic diseases and discovering new biology. As genetic targets are less understood in complex genetic disease, the AI Platform will play an even greater role in identifying novel targets, as well as therapies, to modulate disease.